Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
about
Bisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchFracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisEvidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubManagement of osteoporosis in patients hospitalized for hip fracturesZoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function.Targeting γδ T cells for immunotherapy of HIV diseaseIf you don't take it - it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy.Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.Osteoporosis: the emperor has no clothesCardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional linksBisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.Update on the use of zoledronic acid in the management of osteoporosis.Antiresorptive therapies for osteoporosis: a clinical overview.Current options for the management of postmenopausal osteoporosis.The effect of treatments for osteoporosis on mortality.Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.Fracture mortality: associations with epidemiology and osteoporosis treatment.Fracture liaison services: promoting enhanced bone health care.The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.Risk of long-term infection-related death in clinical osteoporotic vertebral fractures: A hospital-based analysis.Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).Positive Effects of a Sufficient Pre-fracture Serum Vitamin D Level on the Long-Term Survival of Hip Fracture Patients in Finland: A Minimum 11-Year Follow-Up.Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study.Mortality rates after incident non-traumatic fractures in older men and women.Heart failure in patients treated with bisphosphonates.Acute phase response after zoledronic acid is associated with long-term effects on white blood cells.Observational studies--just telling us what we want to hear or telling us where we need to look?Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis.Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.Monocytes and γδ T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial.Mortality After Osteoporotic Fractures: What Proportion Is Caused by Fracture and Is Preventable?Once-yearly zoledronic acid in older men compared with women with recent hip fracture.Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study.
P2860
Q26749442-39A72A1A-0C44-4EEA-AF24-4E77F86805FFQ26782621-F49C5D34-92A6-4CBE-BE7D-D3F538BE9DDBQ30652322-63E0F148-0236-498F-9337-B9F1D91090A3Q34018048-1376AAB7-19D9-4A67-AADF-0365A35FCCA6Q34042003-9707F69D-4E89-4CC1-AB5B-4672FB079804Q34099162-B38E64C0-7213-494F-9ECF-883B97353999Q34284002-755061C6-B2DB-4025-A905-1AA9A0817940Q34505560-A3419580-7FB4-4E92-9157-0749E0101BF0Q34585223-D8263409-F7C9-4DB9-AAD3-058DC81947F4Q35050249-06C1653F-6C04-47FA-B334-DB7C83580277Q35285640-BF03A585-0C7A-475F-AA9E-5B582BAF82C2Q35835844-0338631F-B0F5-4A28-95F2-9863324D5830Q36648170-1B3F8534-2378-4AF4-90C8-85AE99C05226Q37307297-65695D1B-7165-4142-BB60-2F10CFD62380Q37765866-2330C6D0-8BCE-4C5E-9DC6-F1F58BEB77B8Q37926914-2C787402-BD12-487F-AA9F-EE80E223385CQ37931985-0693FFFD-7225-47A3-9B0E-7C1751F327A2Q38053114-9E91E392-8038-4996-9369-ECA1EAC5EC51Q38104993-1BFD8460-591A-4914-931E-F4D8984A200FQ38236887-A4261CF5-CA98-42C2-A9B3-F69B12D610E4Q38252846-9CE9F66A-8111-4158-B077-7A3CF037C482Q38611601-572D67BC-0E28-4993-8535-DA0DC43EA678Q39023035-6D20D6E7-A646-43E8-8B63-631AA319930EQ40100089-C943879E-5572-441B-8156-D717AD0B04E5Q40313121-5B90370A-4298-4B72-9DB7-A2BCEFC95986Q41689098-3BA214D8-826F-46C7-8CF4-8D9A283726F4Q41757089-9A1F33AF-C029-460A-9A2A-CDEC8731D106Q43460593-1C639894-0623-43C4-9420-9609772B7FC2Q44230241-A6BBEAF2-BE45-4559-93FC-AA3BDCCA3D34Q44389690-16A0568C-3E95-4BE7-9E1F-121BAFF1CC31Q45731159-B7ADEAA5-CE70-4DB8-AC46-91D4C151F41BQ46105591-240A661B-354C-46A8-943A-A0B3C9B43307Q47174018-69DE90B4-52CD-4876-A468-2A8C38B1EA9FQ47712068-48EAE70C-E4BD-4C68-BF83-78D23D5462F6Q47912290-C828F331-9820-4F8F-A780-7A661C4708C8Q50555866-491F266A-916E-41CD-A381-F718DA5E513CQ50932570-5C9F3604-A5C4-428A-8139-803356BBD099Q53104294-5DD9AF64-9F25-47AA-BABE-DC43A4208831Q53141719-728D07D8-AFA5-404D-9A8F-59DF0194C73BQ55170820-2F84FA3F-DE35-4761-B5D4-90D3BECDA840
P2860
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@en
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@nl
type
label
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@en
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@nl
prefLabel
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@en
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@nl
P2093
P2860
P356
P1476
Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
@en
P2093
Carl F Pieper
Cathleen S Colón-Emeric
Erik F Eriksen
Jay Magaziner
Kenneth W Lyles
Peter Mesenbrink
Pierre Delmas
Steven Boonen
P2860
P356
10.1359/JBMR.090704
P577
2010-01-01T00:00:00Z